Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EPS (Weighted Average and Diluted) (2023 - 2025)

Historic EPS (Weighted Average and Diluted) for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$0.57.

  • CG Oncology's EPS (Weighted Average and Diluted) fell 9000.0% to -$0.57 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.04, marking a year-over-year increase of 6229.21%. This contributed to the annual value of -$1.41 for FY2024, which is 9099.87% up from last year.
  • According to the latest figures from Q3 2025, CG Oncology's EPS (Weighted Average and Diluted) is -$0.57, which was down 9000.0% from -$0.54 recorded in Q2 2025.
  • CG Oncology's EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.28 during Q2 2024, with a 5-year trough of -$4.47 in Q4 2023.
  • For the 3-year period, CG Oncology's EPS (Weighted Average and Diluted) averaged around -$1.69, with its median value being -$0.54 (2025).
  • Per our database at Business Quant, CG Oncology's EPS (Weighted Average and Diluted) surged by 9287.53% in 2024 and then tumbled by 9285.71% in 2025.
  • Over the past 3 years, CG Oncology's EPS (Weighted Average and Diluted) (Quarter) stood at -$4.47 in 2023, then surged by 88.62% to -$0.51 in 2024, then fell by 12.03% to -$0.57 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.57 in Q3 2025, compared to -$0.54 in Q2 2025 and -$0.45 in Q1 2025.